A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Vosaroxin is a first-in-class anticancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. This study assessed the safety and tolerability of vosaroxin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia. Escalating vosaroxin doses (10-minute infusion;...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica
Hauptverfasser: Lancet, Jeffrey E., Roboz, Gail J., Cripe, Larry D., Michelson, Glenn C., Fox, Judith A., Leavitt, Richard D., Chen, Tianling, Hawtin, Rachael, Craig, Adam R., Ravandi, Farhad, Maris, Michael B., Stuart, Robert K., Karp, Judith E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Ferrata Storti Foundation 2015
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803139/
https://ncbi.nlm.nih.gov/pubmed/25381131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.114769
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge